Semaglutide May Reverse Damage Caused by Osteoarthritis, Study Suggests

A groundbreaking new study suggests that semaglutide—the active ingredient in popular drugs like Ozempic and Wegovy—could do more than help with weight loss and diabetes. It may actually help reverse some of the damage caused by osteoarthritis (OA), the most common form of arthritis worldwide.This research, published in February 2026 in the journal Cell Metabolism, comes from a team of scientists in China and the United States. They found that semaglutide protects and repairs joint cartilage in ways that go beyond just reducing body weight. This discovery could change how doctors treat OA, especially for people who are overweight or have metabolic issues like diabetes.What Is Osteoarthritis?Osteoarthritis happens when the protective cartilage in joints breaks down over time. Cartilage acts like a cushion between bones, allowing smooth movement. When it wears away, bones rub together, causing pain, stiffness, swelling, and loss of mobility. Common spots include knees, hips, hands, and spine.

OA affects about 600 million people globally today. Experts predict that number could reach one billion by 2050 due to aging populations, rising obesity, and more active lifestyles in younger people. Obesity is a major risk factor because extra weight puts stress on joints. It also causes inflammation and metabolic changes that speed up cartilage damage.Current treatments for OA focus on easing symptoms. Pain relievers, physical therapy, injections, or surgery help many people, but they don't fix the underlying problem. There's no cure that rebuilds lost cartilage—until now, perhaps.How Semaglutide WorksSemaglutide is a GLP-1 receptor agonist. It mimics a natural hormone called glucagon-like peptide-1 (GLP-1). This hormone helps control blood sugar by boosting insulin release and slows digestion, which reduces appetite and leads to weight loss.Most people know semaglutide for its big effects on obesity and type 2 diabetes. Studies show it can cut body weight by 15% or more in many users. Less weight means less pressure on joints, which should help OA symptoms. But this new study shows something exciting: benefits that happen even without major weight loss.The researchers used clever experiments to separate weight loss from direct joint effects.Key Findings from Mouse StudiesThe team created mice with obesity (fed a high-fat diet) and then induced OA through surgery (destabilization of the medial meniscus, or DMM model). This mimics human OA in overweight people.

• One group got semaglutide injections.
• Another "pair-fed" group ate the same reduced amount of food as the semaglutide mice to match weight loss—but without the drug.
• A control group got no treatment.

Results were clear:

• Semaglutide-treated mice had much less cartilage damage, fewer bone spurs (osteophytes), milder inflammation in the joint lining (synovium), and lower pain sensitivity.
• The pair-fed mice lost similar weight but showed far less joint protection. This proves the benefits are not just from weight loss.

Looking deeper, the scientists analyzed cartilage tissue. They found changes in nearly 8,300 proteins. The biggest shift was in how cells make energy.

In OA, cartilage cells (called chondrocytes) rely heavily on glycolysis—a fast but inefficient way to produce energy without oxygen. It makes only 2 ATP (energy units) per glucose molecule and builds up harmful byproducts in inflamed joints.Semaglutide flipped this switch. It activated a pathway called the GLP-1R-AMPK-PFKFB3 axis:

• GLP-1R (the receptor semaglutide targets) starts the chain.
• It boosts AMPK, an energy sensor.
• AMPK then influences PFKFB3, shifting cells toward oxidative phosphorylation (OXPHOS).

OXPHOS uses oxygen and produces up to 36 ATP per glucose—much more efficient. Healthier chondrocytes survive better, make more collagen (cartilage's main building block), and repair damage.This metabolic reprogramming helps cells handle stress and inflammation, leading to thicker, healthier cartilage.Evidence from HumansTo test if this works in people, the researchers ran a small randomized pilot trial (registered as ChiCTR2200066291). They enrolled 20 adults aged 50–75 with obesity and knee OA.Participants were split into two groups:

• One got sodium hyaluronate (HA) injections—a common treatment that lubricates joints.
• The other got HA plus semaglutide.

After 24 weeks:

• The HA + semaglutide group reported lower pain scores.
• They showed better knee function and mobility.
• MRI scans revealed thicker cartilage and signs of new cartilage growth in weight-bearing areas (where joints absorb the most shock during walking or standing).

These improvements went beyond what HA alone provides, hinting at a direct protective effect on joints.

Larger studies, like the STEP 9 trial (published in NEJM in 2024), also support semaglutide's benefits for OA. In that 68-week study of over 400 people with obesity and knee OA, semaglutide reduced pain significantly (WOMAC pain score dropped by about 42 points vs. 28 for placebo) and improved physical function—along with substantial weight loss.Why This MattersOsteoarthritis isn't just an "old age" problem anymore. Younger adults are getting it due to obesity, injuries, and inactivity. It leads to chronic pain, disability, reduced quality of life, and high healthcare costs.If semaglutide (or similar GLP-1 drugs) can slow progression, reduce pain, and even rebuild cartilage through metabolic changes, it could offer a game-changing treatment. It targets the root causes—inflammation, poor cell energy, and metabolic stress—rather than just masking symptoms.The study highlights "metabolic osteoarthritis" as a subtype where obesity and diabetes drive faster joint breakdown. Drugs like semaglutide could be especially helpful here.Limitations and Next StepsThis research is promising but early:

• The human trial was small (only 20 people) and short (24 weeks).
• More large-scale, long-term trials are needed to confirm cartilage repair, safety, and benefits in non-obese OA patients.
• Side effects of semaglutide (like nausea, vomiting, or rare serious issues) must be weighed.
• Access and cost remain barriers for many.

Experts call for bigger studies to explore dosing, combinations with other therapies, and effects on other joints (like hips).Looking AheadSemaglutide started as a diabetes drug, became famous for weight loss, and now shows potential for joint health. This fits a growing pattern: GLP-1 drugs benefit heart health, kidneys, liver, and more—often through metabolic and anti-inflammatory effects.For millions with OA, this could mean less pain, better movement, and delayed need for joint replacements. It offers hope that a pill taken weekly might help repair what was once thought irreversible.As research continues, semaglutide and similar medications could become part of standard OA care—especially for those with obesity or metabolic risks. Always talk to a doctor before starting any new treatment.This exciting advance reminds us how connected our body's systems are. Fixing metabolism in one area can heal damage in another. The future of arthritis treatment may be brighter than ever.